Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Status:
Active, not recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of A sintilimab
plus chemotherapy followed by definitive concurrent chemoradiotherapy in locally advanced
esophageal squamous cell carcinoma.